SUMMER 2000 NATAP REPORTS
Reports from Recent Science Conferences:
XIII International AIDS Conference In Durban, South Africa
Resistance Workshop in Sitges, Spain
EASL - European Association for the Study of the Liver in Amsterdam
We encourage you to read the articles on our website which contain more comprehensive treatment information. NATAP has an e-mail treatment news service. When there is breaking treatment news, NATAP will e-mail to you a report of this information. If youíd like to subscribe, free of charge, please send NATAP your e-mail address.
New Drugs: ABT-378, DAPD, BMS-232632, T-20, Tipranavir, PMPA
Abacavir vs. Nelfinavir; Preliminary Data on Abacavir in >100,000 Viral Loads
Ritonavir Double Protease Inhibitor Regimens: Indinavir 400/400, 800/100, 800/200; with Amprenavir
Lipodystrophy: Mitochondrial Toxicity and Lactate (special report from Kees Brinkman, MD; HGH)
Subscriptions
NATAP has a unique mission. We are committed to providing the most comprehensive, accurate and real-time up-to-date treatment information available. Therefore we do not have a set publication schedule. When there are advances in AIDS treatment we will publish them either in this newsletter, on our web site or if they are urgent in a priority fax or e-mail notice.
A subscription to NATAP Reports will allow you to receive a copy of the newsletter as well as an entry on our e-mail list.
Please send us your e-mail address. All our publications are free for those who cannot afford to pay; however, we do appreciate a suggested donation for subscriptions. NATAP is a 501(c)-3 non-profit corporation, so donations are tax-deductible.
NATAPís E-mail address
is info@natap.org
Phone: 212-219-0106 or 1-888-26-NATAP
580 Broadway, Ste 403 NY, NY 10012
The information in this newsletter is only for educational purposes. Before making any treatment decisions one should consult with one's doctor(s). |